Pharmaand Drug Patent Portfolio
Pharmaand owns 1 orange book drug protected by 12 US patents Given below is the list of Pharmaand's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10130636 | High dosage strength tablets of rucaparib | 17 Aug, 2035 | Active |
| US9987285 | High dosage strength tablets of rucaparib | 17 Aug, 2035 | Active |
| US8859562 | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer | 04 Aug, 2031 | Active |
| US10278974 | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one | 10 Feb, 2031 | Active |
| US8754072 | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one | 10 Feb, 2031 | Active |
| US9045487 | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one | 10 Feb, 2031 | Active |
| US9861638 | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one | 10 Feb, 2031 | Active |
| US8071579 | DNA damage repair inhibitors for the treatment of cancer | 12 Aug, 2027 | Active |
| US8143241 | DNA damage repair inhibitors for treatment of cancer | 12 Aug, 2027 | Active |
| US7351701 | Therapeutic compounds | 23 Jul, 2024 | Expired |
| US7531530 | Therapeutic compounds | 23 Jul, 2024 | Expired |
| US6495541 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | 22 Nov, 2023 | Expired |
Latest Legal Activities on Pharmaand's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Pharmaand.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 Nov, 2022 | US9045487 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Oct, 2022 | US10278974 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 04 May, 2022 | US10130636 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 01 Dec, 2021 | US8754072 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Nov, 2021 | US9987285 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 23 Jun, 2021 | US9861638 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 05 Mar, 2021 | US10130636 |
|
Correspondence Address Change
Critical
| 04 Mar, 2021 | US9987285 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 04 Mar, 2021 | US9987285 |
|
Correspondence Address Change
Critical
| 04 Mar, 2021 | US10130636 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 26 Feb, 2021 | US10278974 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 26 Feb, 2021 | US9045487 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 26 Feb, 2021 | US8754072 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 26 Feb, 2021 | US9861638 |
|
Correspondence Address Change
Critical
| 25 Feb, 2021 | US9045487 |
Pharmaand's Drug Patent Litigations
Pharmaand's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 11, 2011, against patent number US8859562. The petitioner , challenged the validity of this patent, with Thomas Helleday as the respondent. Click below to track the latest information on how companies are challenging Pharmaand's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8859562 | October, 2011 |
Decision
(25 Mar, 2014)
| Thomas Helleday | |
Pharmaand Drug Patents' Oppositions Filed in EPO
Pharmaand drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 13, 2012, by Strawman Limited. This opposition was filed on patent number EP04743564A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP16183844A | Apr, 2020 | Generics [UK] Ltd | Granted and Under Opposition |
| EP11708094A | Jun, 2017 | Hexal AG / Sandoz International GmbH | Granted and Under Opposition |
| EP11708094A | Jun, 2017 | Hamm&Wittkopp Patentanwälte PartmbB | Granted and Under Opposition |
| EP04798705A | May, 2012 | Adams, Harvey Vaughan John | Opposition procedure closed |
| EP04798705A | May, 2012 | STRAWMAN LIMITED | Opposition procedure closed |
| EP04743564A | Apr, 2012 | Adams, Harvey Vaughan John | Patent maintained as amended |
| EP04743564A | Apr, 2012 | STRAWMAN LIMITED | Patent maintained as amended |
Pharmaand's Family Patents
Pharmaand Drug List
Given below is the complete list of Pharmaand's drugs and the patents protecting them.
1. Rubraca
Rubraca is protected by 12 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10130636 | High dosage strength tablets of rucaparib |
17 Aug, 2035
(10 years from now)
| Active |
| US9987285 | High dosage strength tablets of rucaparib |
17 Aug, 2035
(10 years from now)
| Active |
| US8859562 | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
04 Aug, 2031
(6 years from now)
| Active |
| US10278974 | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one |
10 Feb, 2031
(6 years from now)
| Active |
| US8754072 | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
10 Feb, 2031
(6 years from now)
| Active |
| US9045487 | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one |
10 Feb, 2031
(6 years from now)
| Active |
| US9861638 | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one |
10 Feb, 2031
(6 years from now)
| Active |
| US8071579 | DNA damage repair inhibitors for the treatment of cancer |
12 Aug, 2027
(2 years from now)
| Active |
| US8143241 | DNA damage repair inhibitors for treatment of cancer |
12 Aug, 2027
(2 years from now)
| Active |
| US7351701 | Therapeutic compounds |
23 Jul, 2024
(4 months ago)
| Expired |
| US7531530 | Therapeutic compounds |
23 Jul, 2024
(4 months ago)
| Expired |
| US6495541 | Tricyclic inhibitors of poly(ADP-ribose) polymerases |
22 Nov, 2023
(1 year, 27 days ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rubraca's drug page